Hoth Therapeutics Inc (HOTH)

$1.36 +0.65 (92.01%)
Market Cap 26.01M
Revenue (ttm) 0.00
Net Income (ttm) -12.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 165,804,703
Avg Vol 6,567,068
Day's Range N/A - N/A
Shares Out 19.13M
Stochastic %K 81%
Beta 0.57
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 239 7459
Address:
720 Monroe Street, Suite E514, Hoboken, United States
Latest News on HOTH
Rocket One regains compliance with Nasdaq listing rules

2026-06-24T12:45:52.000Z - 2 days ago

Rocket One regains compliance with Nasdaq listing rules

Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement

Jun 24, 2026, 8:37 AM EDT - 2 days ago

Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement

Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms

Jun 22, 2026, 8:17 AM EDT - 4 days ago

Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

Jun 15, 2026, 8:11 AM EDT - 11 days ago

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

These space stocks are not SpaceX—but they're blasting off this week in the wake of IPO fever

Jun 12, 2026, 11:52 AM EDT - 14 days ago

These space stocks are not SpaceX—but they're blasting off this week in the wake of IPO fever

ALAB ASTS RKLB SPCE

ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.

Jun 3, 2026, 8:22 AM EDT - 23 days ago

ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.

Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology

Jun 1, 2026, 10:18 AM EDT - 25 days ago

Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology

Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

May 27, 2026, 8:11 AM EDT - 4 weeks ago

Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Jun 29, 2022, 1:25 PM EDT - 4 years ago

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper

Jun 15, 2020, 8:48 AM EDT - 6 years ago

Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper